BNF
E-Alert Facebook Twitter Forward to a friend Sign up to BNF e-news
NOVEMBER 2013 VIEW IN BROWSER
IN THIS ISSUE
BNF eBook More >
Significant changes More >
Changes to Appendix 3 More >
Drug Safety Update More >
How to purchase BNF More >
Latest Tweets More >
Feedback on our e-newsletter More >
Dear Colleague,

Welcome to the BNF newsletter. This month we are pleased to announce the publication of the BNF66 eBook.

Significant updates include new restrictions on the use of metoclopramide following a review of the risks and benefits of its use. Prices for all medicinal products have again been updated - all prices remain consistent with DM+D at the time of publication.

BNF Team
BNF eBook now available
If you have an iPad, iPhone, or iPod touch, you can now download BNF66 as an eBook. This is part of our commitment to ensuring the BNF is available in a convenient format for you. We hope to be able to offer the eBook on other platforms shortly.

The eBook allows you to:

Search the BNF
Bookmark frequently used pages
Annotate the content (iPad only)
Access BNF offline without the need for an internet connection!
BNF 66
£39.99
Download on iBooks
Significant changes
This month's changes to the clinical content of BNF publications are described in three parts:

• BNF & BNFC update should be read by all users of the BNF or BNFC
• BNF update should be read by all users of the BNF
• BNFC update should be read by all users of the BNF for Children

BNF & BNFC update

Metoclopramide: restricted indications, dose and duration of use
The MHRA have issued new restrictions on the use of metoclopramide, following a review of the risks and benefits of its use. The review concluded that the risk of neurological adverse effects such as extrapyramidal disorders and tardive dyskinesia outweigh the benefits in long-term or high-dose treatment.

In adults, metoclopramide should now only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine. Children should only receive metoclopramide as a second-line option for prevention of delayed chemotherapy-induced nausea and vomiting and for treatment of established postoperative nausea and vomiting. Metoclopramide is contra-indicated in children aged under 1 year. Further restrictions have been made to dose, duration of use and administration for both adults and children. For full details see MHRA advice in BNF section 4.6.

BNF update

Ustekinumab
Ustekinumab, a monoclonal antibody, is now licensed for the symptomatic treatment of active psoriatic arthritis (in combination with methotrexate or alone) in adults who have had an inadequate response to one or more disease-modifying antirheumatic drugs. This is in addition to its existing indication for the treatment of plaque psoriasis. For more information see Ustekinumab.

Other changes
To review other changes in the BNF, click on changes.

BNFC update

Canakinumab
Canakinumab, a monoclonal antibody, is now licensed for the treatment of active juvenile idiopathic arthritis (in combination with methotrexate or alone) in children who have had an inadequate response to NSAIDs and systemic corticosteroids. This is in addition to its existing indication for the treatment of cryopyrin-associated periodic syndromes. For more information see Canakinumab.

Other changes
To review other changes in BNFC, click on changes.

return to top

Changes to Appendix 3: Cautionary and advisory labels
The following products in the Appendix 3 list of products and their labels have been updated:

Domperidone - Dytac - Efexor - Pripsen - piperazine - venlafaxine - sildenafil - Nipatra - Motillium

return to top

Drug Safety Update
Drug Safety UpdateDrug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.

return to top

How to purchase BNF
Purchase a print copy Purchase print copies
For the latest edition visit the Pharmaceutical Press website.
Purchase a print subscription Purchase a print subscription - and save up to 31%
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes. To order bulk subscriptions contact pharmaceutical.press@rpharms.com.
BNF online BNF online
Outside the UK, content is available via a subscription to MedicinesComplete. For more information contact sales@medicinescomplete.com

Latest Tweets @BNFormulary
Pharmaceutical Press NHS England @NHSEngland
On 7 Nov we are hosting our 2nd w/s to develop & improve quality of services for Transgender people #NHSGenderID http://bit.ly/12spkAW
Tue Nov 05 10:20
Pharmaceutical Press Pharmaceutical Press @PharmPress
The 2014 edition of the Orange Guide is now available to pre-order. The essential reference for the pharma industry! http://goo.gl/RIT2Rh
Wed Oct 30 15:28
Pharmaceutical Press BMJ @bmj_latest
BBC News - HIV antibodies 'have potent impact' http://bbc.in/19cxJeV
Tue Oct 29 12:38

return to top

Feedback on our e-newsletter
Please let us know if there are any issues that you would like us to address in e-newsletters. We welcome your feedback. If you have any comments or suggestions please let us know at enewsletter@bnf.org.
Subscribe to this e-newsletter.

return to top

Related Products
MedicinesComplete BNF on FormularyComplete Pharmaceutical Press
BNF Copyright © 2013 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved.

Terms of use
BNF for Children Copyright © 2013 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved.

Terms of use
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 1 Lambeth High Street, London, SE1 7JN, UK